Epizyme announces US FDA accelerated approval of TAZVERIK for relapsed/refractory follicular lymphoma

This article was originally published here

Adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two

The post Epizyme announces US FDA accelerated approval of TAZVERIK for relapsed/refractory follicular lymphoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply